Publications by Oncolines Scientists on Cell Panel Profiling, SynergyFinder, Mechanistic Cell Biology:

  • Conlon et al. (2021) Comparative analysis of drug response and gene profiling of the HER2-targeted tyrosine kinase inhibitors, British Journal of Cancer, 124 (7):1249-1259. (collaboration with Dublin City University and Puma Biotechnology, Inc.)
  • den Ouden et al. (2020) Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites, Oncotarget, 11:4570-4581. (collaboration with Radboud University Medical Center)
  • Libouban et al. (2017) Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines, Oncotarget, 8 (24):38309–38325. (collaboration with Netherlands Cancer Institute)
  • de Roos JA, Uitdehaag JC, de Man AP, Buijsman RC, Zaman GJR, inventors; Netherlands Translational Research Center B.V., assignee. Prognostic biomarkers for TTK inhibitor chemotherapy. Patent WO 2016/166255 A1. 2016 Oct 20

References by our Clients to Oncolines, SynergyFinder, Mechanistic Cell Biology:

  • van der Zwet et al. (2021) MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance, Leukemia, online first, May 18, 2021. (Affiliation: Prinses Máxima Center for Pediatric Oncology)
  • van der Zwet et al. (2020) The central role of MAPK-ERK signalling in IL7-dependent and IL7-independent steroid resistance reveals a broad application of MEK-inhibitors compared to JAK1/2-inhibition in T-ALL, Oral presentation, ASH Annual Meeting 2020 (affiliation: Prinses Máxima Center for Pediatric Oncology)
  • Cordo et al. (2020) Phospho-proteomic profiling of T-Cell Acute Lymphoblastic Leukemia identifies targetable kinase activities and novel treatment combination strategies, Oral presentation, ASH Annual Meeting 2020 (Affiliation: Prinses Máxima Center for Pediatric Oncology)
  • Borsari et al. (2019) Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl−Pyrimidine Moiety, ACS Medicinal Chemistry Letters, 10:1473-1479. (Affilitations: University of Basel, PIQUR Therapeutics AG)
  • Rageot et al. (2019) (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase, Journal of Medicinal Chemistry, 62 (13):6241-6261. (Affiliations: University of Basel, PIQUR Therapeutics AG)
  • Grünewald et al. (2019) Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models, International Journal of Cancer, 145 (5): 346-1357. (Affiliation: Bayer AG)
  • Gentile et al. (2018) A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study, Pharmaceuticals, 11 (1):22. (Affiliation: University of Alberta)
  • Bohnacker et al. (2017) Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention, Nature Communications, 8:14683. (Affiliation: University of Basel)
  • Canté-Barrett et al. (2016) MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia, Leukemia, 30:1832-1843. (Affiliations: Erasmus MC, NTRC)
  • Maia et al. (2015) Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model, Annals of Oncology, 26 (10):2180-2192. (Affiliations: Netherlands Cancer Institute, NTRC)
back to home